Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia: Part I. In vivo studies
- 30 November 2004
- journal article
- Published by Elsevier BV in Leukemia Research
- Vol. 28 (11), 1125-1136
- https://doi.org/10.1016/j.leukres.2004.03.003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Chronic myelogenous leukemia: A review and update of therapeutic strategiesCancer, 2003
- Advanced-phase chronic myeloid leukemiaSeminars in Hematology, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurinExperimental Cell Research, 1990
- Selective sensitivity to tiazofurin of human leukemic cellsBiochemical Pharmacology, 1986
- Purine metabolism in myeloid precursor cells during maturation. Studies with the HL-60 cell line.JCI Insight, 1983
- Induced maturation of the human promyelocytic leukemia cell line, HL-60, by 2-β-D-ribofuranosylselenazole-4-carboxamideBiochemical and Biophysical Research Communications, 1983
- Conversion of 2-β-D-ribofuranosylselenazole-4-carboxamide to an analogue of nad with potent imp dehydrogenase-inhibitory propertiesBiochemical Pharmacology, 1983
- 2-.beta.-D-ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastasesJournal of Medicinal Chemistry, 1982